LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Relay Therapeutics Inc

Fermé

SecteurSoins de santé

4.06 0.25

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.97

Max

4.09

Chiffres clés

By Trading Economics

Revenu

6.7M

-70M

Ventes

-7M

677K

Marge bénéficiaire

-10,395.126

Employés

197

EBITDA

8M

-77M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+237.68% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-6.8M

619M

Ouverture précédente

3.81

Clôture précédente

4.06

Sentiment de l'Actualité

By Acuity

50%

50%

173 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Relay Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 sept. 2025, 23:59 UTC

Acquisitions, Fusions, Rachats

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sept. 2025, 22:02 UTC

Principaux Mouvements du Marché

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sept. 2025, 17:01 UTC

Principaux Mouvements du Marché

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sept. 2025, 17:01 UTC

Principaux Mouvements du Marché

Tron Shares Rise After New Investment From Bravemorning

8 sept. 2025, 16:14 UTC

Principaux Mouvements du Marché

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sept. 2025, 16:13 UTC

Principaux Mouvements du Marché

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sept. 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 sept. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8 sept. 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sept. 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sept. 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sept. 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sept. 2025, 21:47 UTC

Principaux Mouvements du Marché

Microsoft Signs $17.4B AI Deal With Nebius

8 sept. 2025, 21:33 UTC

Acquisitions, Fusions, Rachats

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sept. 2025, 21:20 UTC

Acquisitions, Fusions, Rachats

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sept. 2025, 21:19 UTC

Acquisitions, Fusions, Rachats

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sept. 2025, 21:18 UTC

Acquisitions, Fusions, Rachats

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sept. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

8 sept. 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sept. 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sept. 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sept. 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 sept. 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sept. 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sept. 2025, 16:59 UTC

Market Talk
Acquisitions, Fusions, Rachats

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sept. 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sept. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 sept. 2025, 16:16 UTC

Résultats

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 sept. 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparaison

Variation de prix

Relay Therapeutics Inc prévision

Objectif de Prix

By TipRanks

237.68% hausse

Prévisions sur 12 Mois

Moyen 13.71 USD  237.68%

Haut 19 USD

Bas 4 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

9 ratings

7

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

2.88 / 3.285Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Sentiment

By Acuity

173 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat